Inoue H, Kaku K, Matsutani A, Tao T, Ayame H, Kaneko T
3rd Department of Medicine, Yamaguchi University School of Medicine, Ube, Japan.
Endocr J. 1994 Feb;41(1):75-82. doi: 10.1507/endocrj.41.75.
Effects of vanadate on liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PF-2-K/F-2,6-P2ase) mRNA and protein inductions were examined in streptozotocin (STZ)-induced diabetic rats. In diabetic rats at one week after STZ (60 mg/kg body weight), the liver 6PF-2-K activity was decreased to 22% of the control. The enzyme protein was also decreased to 31% of the control, but the reduction in mRNA was not significant. Treatment of diabetes with vanadate (10 mg/kg BW, i.v., every 8 h), as well as insulin (10 u/kg BW, s.c., every 8 h), increased the 6PF-2-K activity and the enzyme protein content, though it was not completely restored to the control level. 68% of the control was the figure for enzyme activity and 65% of the control for protein content after 24-h of treatment. On the other hand, vanadate, like insulin, increased enzyme mRNA content to a higher level than the control (140% of the control). The present results indicate that vanadate, like insulin, modulates the liver 6PF-2-K/Fru-2,6-P2ase gene expression, and stimulated protein induction contributes to the regulation of its enzyme activity, resulting in amelioration of the deranged carbohydrate metabolism in the diabetic state.
研究了钒酸盐对链脲佐菌素（STZ）诱导的糖尿病大鼠肝脏6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶（6PF-2-K/F-2,6-P2ase）mRNA和蛋白质诱导的影响。在STZ（60mg/kg体重）注射后一周的糖尿病大鼠中，肝脏6PF-2-K活性降至对照组的22%。酶蛋白也降至对照组的31%，但mRNA的减少不显著。用钒酸盐（10mg/kg体重，静脉注射，每8小时一次）以及胰岛素（10u/kg体重，皮下注射，每8小时一次）治疗糖尿病，可增加6PF-2-K活性和酶蛋白含量，尽管未完全恢复到对照水平。治疗24小时后，酶活性为对照组的68%，蛋白质含量为对照组的65%。另一方面，钒酸盐与胰岛素一样，可使酶mRNA含量增加至高于对照组的水平（为对照组的140%）。目前的结果表明，钒酸盐与胰岛素一样，可调节肝脏6PF-2-K/Fru-2,6-P2ase基因表达，刺激蛋白质诱导有助于调节其酶活性，从而改善糖尿病状态下紊乱的碳水化合物代谢。
